Loading clinical trials...

UNKNOWNPHASE4

Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.

NCT00857038•Medical Center Alkmaar

View on ClinicalTrials.gov

Summary

COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.

Detailed Description

Rationale: COPD is a disease characterized by chronic inflammation and irreversible airway obstruction. Chronic inflammation lead to degradation of extracellular matrix and hereby destruction of lung parenchyma. Tetracyclines are known for their anti-inflammatory properties in diseases such as rheumatoid arthritis. Objective: To assess the effect of doxycycline on markers of neutrophilic inflammation and proteolytic activity in induced sputum of stable GOLD II and III COPD patients. Study population: Thirty patients with stable GOLD II COPD. Intervention: Placebo versus doxycycline in randomised design.

Eligibility

Age

41 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•GOLD II or III COPD (GOLD II: FEV1/FVC \< 70%; 50% \< FEV1 \< 80% predicted, GOLD III: FEV1/FVC \< 70%; 30% \< FEV1 \< 50% predicted ).
•Stable disease (no exacerbations in the last 3 months).
•Age \> 40 yrs.
•Written informed consent.

Exclusion Criteria

•Infections and/or use of antibiotics in the last month.
•Bacterial colonization of the airways, proven by sputum cultures or broncho-alveolar lavage (BAL).
•Allergy for tetracyclines or a history of substantial side-effects.
•Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung cancer, bronchiectasis).
•Acute exacerbation of COPD as defined by Anthonisen et al. \[10\].
•Signs and/or symptoms of a current respiratory or non-respiratory infection.
•Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the last month.

Locations (1)

Medical Center Alkmaar

Alkmaar, North Holland, Netherlands

Key Dates

Start Date

April 1, 2009

Primary Completion Date

August 1, 2009

Completion Date

January 1, 2010

Last Updated

March 6, 2009

Enrollment

ESTIMATED participants

Conditions

Chronic Obstructive Pulmonary DiseaseInflammationPulmonary Emphysema

Interventions

Doxycycline

DRUG

Placebo

DRUG

Contacts

Wim G Boersma, MD

CONTACT

0031725482750 w.boersma@mca.nl

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGPHASE4

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647

Autoimmunity, Inflammation

View study

RECRUITING

Immune Cell Response to Stimuli

NCT00397280

Inflammation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

Secukinumab Open Label Roll-over Extension Protocol

Immune Cell Response to Stimuli

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Skin Barrier Function and Inflammation in Aging: The BIA Study

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)